Literature DB >> 10683279

Complement component C1q modulates the phagocytosis of Abeta by microglia.

S D Webster1, A J Yang, L Margol, W Garzon-Rodriguez, C G Glabe, A J Tenner.   

Abstract

Recent studies showing that microglia internalize the amyloid beta-peptide (Abeta) suggest that these cells have the potential for clearing Abeta deposits in Alzheimer's disease, and mechanisms that regulate the removal of Abeta may therefore be of clinical interest. Previous studies from this laboratory showing that C1q enhances phagocytosis of cellular targets by rat microglia prompted the current investigations characterizing the effects of C1q on microglial phagocytosis of Abeta. Microglia were shown to phagocytose Abeta1-42, in agreement with observations of other investigators. Uptake of Abeta1-42 was observed for concentrations of 5-50 microM, and phagocytosis of peptides containing (14)C or fluorescein (FM) labels was not affected by the interaction of microglia with C1q-coated surfaces. However, inclusion of C1q (125 nM-1.4 microM) in solutions of 50 microM Abeta1-42 inhibited the uptake of (14)C-Abeta1-42 and FM-Abeta1-42, suggesting that C1q blocks the interaction of Abeta with microglia. Uptake of Abeta was partially blocked by the scavenger receptor ligands polyinosinic acid and maleylated BSA. Inhibition of Abeta uptake by C1q may contribute to the accumulation of fibrillar, C1q-containing plaques that occurs in parallel with disease progression. These data suggest that mechanisms which interfere with the binding of C1q to Abeta may be of therapeutic value both through inhibition of the inflammatory events resulting from complement activation and via altered access of Abeta sites necessary for ingestion by microglia. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683279     DOI: 10.1006/exnr.1999.7260

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  49 in total

1.  Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model.

Authors:  Ken-ichiro Fukuchi; Mary Ann Accavitti-Loper; Hong-Duck Kim; Kazuki Tahara; Yunpeng Cao; Terry L Lewis; Robert C Caughey; Helen Kim; Robert Lalonde
Journal:  Biochem Biophys Res Commun       Date:  2006-05-26       Impact factor: 3.575

2.  Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.

Authors:  Hee Young Hwang; Marcus R Duvall; Stephen Tomlinson; Robert J Boackle
Journal:  Mol Immunol       Date:  2008-03-03       Impact factor: 4.407

3.  Therapeutic effects of glatiramer acetate and grafted CD115⁺ monocytes in a mouse model of Alzheimer's disease.

Authors:  Yosef Koronyo; Brenda C Salumbides; Julia Sheyn; Lindsey Pelissier; Songlin Li; Vladimir Ljubimov; Michelle Moyseyev; David Daley; Dieu-Trang Fuchs; Michael Pham; Keith L Black; Altan Rentsendorj; Maya Koronyo-Hamaoui
Journal:  Brain       Date:  2015-06-06       Impact factor: 13.501

Review 4.  From development to dysfunction: microglia and the complement cascade in CNS homeostasis.

Authors:  Matthew K Zabel; Wolff M Kirsch
Journal:  Ageing Res Rev       Date:  2013-02-16       Impact factor: 10.895

Review 5.  Amyloidosis associated with cerebral amyloid angiopathy: cell signaling pathways elicited in cerebral endothelial cells.

Authors:  Jorge Ghiso; Silvia Fossati; Agueda Rostagno
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 6.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

7.  Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology.

Authors:  Elizabeth E Spangenberg; Rafael J Lee; Allison R Najafi; Rachel A Rice; Monica R P Elmore; Mathew Blurton-Jones; Brian L West; Kim N Green
Journal:  Brain       Date:  2016-02-26       Impact factor: 13.501

8.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.

Authors:  Dan Frenkel; Ruth Maron; David S Burt; Howard L Weiner
Journal:  J Clin Invest       Date:  2005-08-11       Impact factor: 14.808

Review 9.  The Neuro-Immune-Regulators (NIREGs) Promote Tissue Resilience; a Vital Component of the Host's Defense Strategy against Neuroinflammation.

Authors:  Yosra Bedoui; Jim W Neal; Philippe Gasque
Journal:  J Neuroimmune Pharmacol       Date:  2018-06-16       Impact factor: 4.147

Review 10.  Why pleiotropic interventions are needed for Alzheimer's disease.

Authors:  Sally A Frautschy; Greg M Cole
Journal:  Mol Neurobiol       Date:  2010-05-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.